0 CHECKOUT

Colorectal Cancer Drug Pipeline Update

  • ID: 1197066
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.

There are today 426 companies plus partners developing 509 drugs targeting colorectal cancer in development. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 211 drugs. Colorectal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 346 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 334 out of the 335 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb